3phala Ayurcentre Private Limited

3phala Ayurcentre Private Limited is a privately held Indian company specializing in the export of Ayurvedic and herbal pharmaceutical formulations. Established on November 16, 2018, the company is registered under the Corporate Identification Number (CIN) U74999TN2018PTC125961. Headquartered in Chennai, Tamil Nadu, at New No. 19, Old No. 61, 27th Street, L Block, Anna Nagar East, the company operates within the business services sector. The authorized share capital is ₹1,000,000, with a paid-up capital of ₹100,000. As of the latest available data, the company remains active and compliant with regulatory requirements.

Specific details regarding the manufacturing facilities of 3phala Ayurcentre Private Limited are not publicly disclosed. The company's export activities, as indicated by trade data, suggest that it may operate through contract manufacturing or third-party facilities. The absence of publicly available information on in-house manufacturing capabilities limits a comprehensive assessment of its production capacities and specializations.

The company's leadership comprises directors Bhuvaneswari Hariharan, Periyasami Karthikeyan, Periyasamy Pachaiyammal, and Periyasami Marimuthu Manmalai. However, specific roles such as CEO, CFO, and other key executive positions are not publicly detailed. The lack of publicly available information on the executive team hinders a thorough understanding of the company's strategic direction and management structure.

3phala Ayurcentre Private Limited's export data indicates shipments to various international markets, including Singapore. For instance, in July 2025, the company exported 50 bottles of Pathyakshadhatryadi Kashayam (200ml each) to Singapore. However, there is no publicly available information regarding the company's regulatory filings, approvals, or market access status in the United States, European Union, United Kingdom, Australia, or Japan. The absence of such data suggests limited or no presence in these regulated markets.

The company's export activities, particularly to Singapore, indicate a presence in Southeast Asia. However, there is no publicly available information regarding its penetration into African, Latin American, or other Southeast Asian markets. Additionally, the lack of data on WHO prequalification status suggests that the company may not have pursued this certification, potentially limiting access to certain international markets.

The company's export data primarily reflects shipments to Singapore, indicating a focused geographic strategy. The absence of exports to other regions suggests a concentration risk, potentially exposing the company to market fluctuations in its primary export destination. Without information on diversification efforts or strategic direction, it is challenging to assess the company's long-term geographic strategy.

There is no publicly available information regarding 3phala Ayurcentre Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The lack of such data suggests that the company may not have pursued FDA approvals, potentially limiting its access to the U.S. pharmaceutical market.

The company's export data does not indicate WHO prequalification or EU Good Manufacturing Practice (GMP) certifications. The absence of such certifications may restrict the company's ability to access certain international markets that require these standards.

Specific details regarding 3phala Ayurcentre Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly available. The lack of such information limits the ability to assess the company's compliance with Indian regulatory requirements.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with 3phala Ayurcentre Private Limited. The absence of such data suggests that the company may not have faced significant regulatory actions in its export markets.

The Ayurvedic and herbal pharmaceutical export market is competitive, with numerous companies offering similar products. Without specific data on competitors' market shares or a head-to-head analysis, it is challenging to position 3phala Ayurcentre Private Limited within the competitive landscape.

The company's focus on Ayurvedic and herbal pharmaceutical formulations positions it within a niche market segment. However, without detailed information on product offerings, quality standards, or unique selling propositions, it is difficult to identify specific competitive advantages or differentiators.

The company's export data suggests a focus on Ayurvedic and herbal pharmaceutical formulations. However, without information on its strategic direction, such as emphasis on generics, specialty products, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, it is challenging to assess its current strategic position or future outlook.

The company's export data indicates shipments to Singapore, suggesting a track record in international trade. However, the limited volume of exports and the absence of information on export consistency or reliability indicators make it difficult to assess the company's overall performance as a supplier.

Importers should verify the following certifications when considering 3phala Ayurcentre Private Limited as a supplier:

• FDA Approval: To verify FDA approval, consult the FDA's official database or contact the company directly.

• WHO-GMP Certification: Check the WHO's official website or contact the company for certification details.

• EU GMP Certification: Verify through the European Medicines Agency (EMA) or the company's official communications.

• ISO Certification: Request ISO certification details from the company or verify through the International Organization for Standardization (ISO) database.

When conducting due diligence on 3phala Ayurcentre Private Limited, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's compliance with relevant regulatory bodies, including the FDA, WHO, and EU authorities.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities, quality control measures, and adherence to Good Manufacturing Practices (GMP).

• Review Financial Health: Analyze the company's financial statements, credit history, and payment terms.

• Check References: Obtain references from other clients or partners to assess the company's reliability and reputation.

• Inspect Product Quality: Request product samples and conduct quality assessments to ensure they meet required standards.

• Monitor for Red Flags: Be alert to any inconsistencies in documentation, unexplained delays, or lack of transparency, which may indicate potential issues.

By following this checklist, importers can make informed decisions and mitigate potential risks associated with partnering with 3phala Ayurcentre Private Limited.